Boehringer Ingelheim International GmbH
🇩🇪Germany
Cathepsin C Inhibitor BI 1291583 Shows Promise in Reducing Bronchiectasis Exacerbations
Phase 2 AIRLEAF trial results indicate that BI 1291583, a cathepsin C inhibitor, reduces the risk of pulmonary exacerbations in adults with bronchiectasis.